Status:
RECRUITING
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Conditions:
Post Bariatricsurgery
Hypoglycemia
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been re...
Detailed Description
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been re...
Eligibility Criteria
Inclusion
- Hypoglycemic RYGB patients with documented blood glucose level \<50 mg/dl
- Asymptomatic individuals with bariatric surgery
- Healthy non-surgical patients with no personal history of diabetes
- Subjects must physically be able to come to our clinical research center at Cedars-Sinai Medical Center
Exclusion
- Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \<11g/dL); prisoners or institutionalized individuals; type 2 diabetes melitis; development of any serious medical or psychiatric illness during recruitment or studies;
- RYGB patients will also be disqualified if they have gastric outlet obstruction or severe diarrhea
- Healthy non-surgical patients with personal history of diabetes
- For administration of atropine, the following exclusions also apply:
- History of glaucoma
- Uncontrolled hypertension (any subjects with BP\>140/90 and history of dyslipidemia
- Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)
- Myasthenia gravis
- Brain pathology
- Enlarged prostate in men
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00992901
Start Date
October 1 2009
End Date
August 1 2027
Last Update
September 9 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Diabetes Institute - University Health System
San Antonio, Texas, United States, 78207
2
South Texas Veterans Health Care System
San Antonio, Texas, United States, 78229